AR078216A1 - Metodos para la inhibicion de la neurodegeneracion - Google Patents
Metodos para la inhibicion de la neurodegeneracionInfo
- Publication number
- AR078216A1 AR078216A1 ARP100100459A ARP100100459A AR078216A1 AR 078216 A1 AR078216 A1 AR 078216A1 AR P100100459 A ARP100100459 A AR P100100459A AR P100100459 A ARP100100459 A AR P100100459A AR 078216 A1 AR078216 A1 AR 078216A1
- Authority
- AR
- Argentina
- Prior art keywords
- app
- polypeptide
- neurodegeneration
- inhibited
- exposure
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Se presentan métodos para la deteccion de compuestos que inhiben la neurodegeneracion. El desprendimiento de APP puede ser un marcador util para la neurodegeneracion, y los compuestos que inhiben el desprendimiento de APP son utiles como inhibidores de la neurodegeneracion. Dichos compuestos pueden ser utiles en el tratamiento y la prevencion de diversos trastornos y enfermedades neurologicos, y del dano neuronal, y pueden aumentar el crecimiento, la regeneracion o la supervivencia de tejido o células neuronales de mamíferos. Reivindicacion 1: Un método para la inhibicion de la neurodegeneracion, que comprende: (a) la exposicion de polipéptido DR6 y/o polipéptido APP a uno o más antagonistas de DR6 en condiciones donde la union de DR6 a APP es inhibida; (b) la exposicion de polipéptido p75 y/o polipéptido APP a uno o más antagonistas de p75 en condiciones donde la union de APP a p75 es inhibida; o (c) la exposicion de polipéptido DR6 polipéptido p75. y/o polipéptido APP a uno o más antagonistas de DR6 y p75, en condiciones donde la union de DR6 y p75 a APP es inhibida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15354009P | 2009-02-18 | 2009-02-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR078216A1 true AR078216A1 (es) | 2011-10-26 |
Family
ID=42634431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100100459A AR078216A1 (es) | 2009-02-18 | 2010-02-17 | Metodos para la inhibicion de la neurodegeneracion |
Country Status (13)
Country | Link |
---|---|
US (1) | US20120076785A1 (es) |
EP (1) | EP2399135A4 (es) |
JP (1) | JP2012518042A (es) |
KR (1) | KR20120011841A (es) |
CN (1) | CN102326083A (es) |
AR (1) | AR078216A1 (es) |
AU (1) | AU2010216107A1 (es) |
BR (1) | BRPI1005403A2 (es) |
CA (1) | CA2752171A1 (es) |
IL (1) | IL214647A0 (es) |
MX (1) | MX2011007567A (es) |
TW (1) | TW201034684A (es) |
WO (1) | WO2010096470A2 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010062904A2 (en) | 2008-11-25 | 2010-06-03 | Biogen Idec Ma Inc. | Use of dr6 and p75 antagonists to promote survival of cells of the nervous system |
AR078986A1 (es) * | 2009-11-12 | 2011-12-14 | Genentech Inc | Un metodo para promover la densidad de espinas dendriticas |
US9238796B2 (en) | 2010-06-04 | 2016-01-19 | Toagosei Co. Ltd. | Cell growth-promoting peptide and use thereof |
US9320793B2 (en) * | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
WO2013180011A1 (ja) | 2012-05-28 | 2013-12-05 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
JP6311935B2 (ja) * | 2012-10-18 | 2018-04-18 | 東亞合成株式会社 | 2型tnf受容体の発現を抑制する合成ペプチド及びその利用 |
US10295547B2 (en) | 2013-03-14 | 2019-05-21 | University Of Florida Research Foundation, Incorporated | Use and treatment of di-amino acid repeat-containing proteins associated with ALS |
EP3685662B9 (en) * | 2015-03-16 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Cell of a rodent exhibiting diminished upper and lower motor neuron function and sensory perception |
AU2016235685B2 (en) * | 2015-03-26 | 2019-04-18 | Suzhou Auzone Biological Technology Co., Ltd | Method of diagnosis or treatment of neurological disorders with p75ECD and/or p75 |
US10509045B2 (en) | 2015-05-29 | 2019-12-17 | University Of Florida Research Foundation, Incorporated | Methods for diagnosing Huntington's disease |
AU2017246643B2 (en) | 2016-04-04 | 2022-08-04 | University Of Florida Research Foundation, Incorporated | Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation |
EP3612190A4 (en) | 2017-04-17 | 2021-01-20 | University of Florida Research Foundation, Incorporated | REGULATION OF RAN TRANSLATION THROUGH PKR AND EIF2A-P WAYS |
CA3076214A1 (en) | 2017-09-26 | 2019-04-04 | University Of Florida Research Foundation, Incorporated | Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders |
CN114958760A (zh) * | 2021-02-23 | 2022-08-30 | 南京启真基因工程有限公司 | 一种构建阿尔兹海默症模型猪的基因编辑技术及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2086165A1 (en) * | 1992-04-09 | 1993-10-10 | Paul P. Tamburini | Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein |
WO1997037228A1 (en) * | 1996-03-29 | 1997-10-09 | The Trustees Of Boston University | Methods for diagnosing and treating alzheimer's disease |
FI991197A0 (fi) * | 1999-05-27 | 1999-05-27 | Mart Saarma | Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa |
US7241570B2 (en) * | 2001-03-23 | 2007-07-10 | University Of Utah Research Foundation | Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use |
WO2003040183A2 (en) * | 2001-11-09 | 2003-05-15 | The Genetics Company, Inc | Compounds for the diagnosis/prevention/treatment of alzheimer's disease |
US20050069540A1 (en) * | 2001-12-17 | 2005-03-31 | Jinqi Liu | Treating b-cell mediated diseases by modulating dr6 activity |
US20040191291A1 (en) * | 2003-03-28 | 2004-09-30 | Masaya Tohyama | Composition and method for nerve regeneration |
CN1849132A (zh) * | 2003-09-10 | 2006-10-18 | 伦敦大学国王学院 | 调节神经元生长的化合物以及它们的用途 |
EP1682170A2 (en) * | 2003-11-07 | 2006-07-26 | Lay Line Genomics SpA | Compositions able to prevent neurodegenerative processes and methods of assaying the same |
AU2004324236B2 (en) * | 2004-10-22 | 2010-12-09 | Neuregenix Limited | Neuron regeneration |
CA2595800C (en) * | 2005-01-24 | 2014-07-08 | Cambridge Antibody Technology Limited. | Specific binding members for ngf |
CN101273060A (zh) * | 2005-06-24 | 2008-09-24 | 美国政府(由卫生和人类服务部、国立卫生研究院的部长所代表) | 通过靶向肿瘤坏死因子受体的前配体装配域(plad)来缓解炎性关节炎 |
US20100203044A1 (en) * | 2006-12-22 | 2010-08-12 | Anatoly Nikolaev | Dr6 antagonists and uses thereof in treating neurological disorders |
WO2010062904A2 (en) * | 2008-11-25 | 2010-06-03 | Biogen Idec Ma Inc. | Use of dr6 and p75 antagonists to promote survival of cells of the nervous system |
-
2010
- 2010-02-12 TW TW099104907A patent/TW201034684A/zh unknown
- 2010-02-17 KR KR1020117019093A patent/KR20120011841A/ko not_active Application Discontinuation
- 2010-02-17 CN CN2010800082730A patent/CN102326083A/zh active Pending
- 2010-02-17 JP JP2011551186A patent/JP2012518042A/ja active Pending
- 2010-02-17 WO PCT/US2010/024458 patent/WO2010096470A2/en active Application Filing
- 2010-02-17 AR ARP100100459A patent/AR078216A1/es unknown
- 2010-02-17 CA CA2752171A patent/CA2752171A1/en not_active Abandoned
- 2010-02-17 EP EP10744246A patent/EP2399135A4/en not_active Withdrawn
- 2010-02-17 MX MX2011007567A patent/MX2011007567A/es unknown
- 2010-02-17 AU AU2010216107A patent/AU2010216107A1/en not_active Abandoned
- 2010-02-17 US US13/202,144 patent/US20120076785A1/en not_active Abandoned
- 2010-02-17 BR BRPI1005403A patent/BRPI1005403A2/pt not_active IP Right Cessation
-
2011
- 2011-08-15 IL IL214647A patent/IL214647A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2399135A4 (en) | 2012-10-17 |
EP2399135A2 (en) | 2011-12-28 |
JP2012518042A (ja) | 2012-08-09 |
BRPI1005403A2 (pt) | 2016-10-04 |
WO2010096470A4 (en) | 2011-04-14 |
WO2010096470A2 (en) | 2010-08-26 |
WO2010096470A3 (en) | 2010-12-16 |
CA2752171A1 (en) | 2010-08-26 |
AU2010216107A1 (en) | 2011-08-18 |
MX2011007567A (es) | 2011-09-28 |
CN102326083A (zh) | 2012-01-18 |
KR20120011841A (ko) | 2012-02-08 |
IL214647A0 (en) | 2011-09-27 |
TW201034684A (en) | 2010-10-01 |
US20120076785A1 (en) | 2012-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR078216A1 (es) | Metodos para la inhibicion de la neurodegeneracion | |
ECSP21027049A (es) | Inhibidores de la proteína tirosina fosfatasa | |
PH12018500045A1 (en) | Compositions and methods for treating and diagnosing asthma | |
PE20070335A1 (es) | Benzimidazoles sustituidos y metodos para su preparacion | |
UA111933C2 (uk) | Піролопіридини як інгібітори кінази | |
GT200800202A (es) | Quinazolinas para la inhibicion de pdk1 | |
TR201911199T4 (tr) | Hücre büyümesini arttırmak için tedavi. | |
UY32967A (es) | Compuestos heterocíclicos fusionados como moduladores del receptor de la orexina | |
UA100262C2 (uk) | Інгібітори активності протеїнтирозинкінази | |
DOP2017000053A (es) | Derivados de benzodiazepina citotóxicos | |
GT200800265A (es) | Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas. | |
BR112015017174A2 (pt) | preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico | |
AR064501A1 (es) | Antagonistas del dr6 (receptor de muerte 6) y usos de los mismos en el tratamiento de trastornos neurologicos | |
MX2011009167A (es) | Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas. | |
EA200970931A1 (ru) | Аналоги гетероариламидов | |
ATE500319T1 (de) | Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden | |
UY32968A (es) | Compuestos heterocíclicos fusionados como moduladores del receptor de orexina | |
UY29077A1 (es) | Amidas sustituidas de ácido tienopirrolcarboxílico, amidas del ácido pirrolotiazolcarboxílico y análogos relacionados como inhibidores de la caseína cinasa ie(epsilon) | |
SG11201809744YA (en) | Method for improving salt tolerance of plant | |
WO2011091366A3 (en) | Methods of treating or preventing periodontitis and diseases associated with periodontitis | |
UY29212A1 (es) | Azabenzoxazoles para el tratamiento de trastornos del snc | |
MY157319A (en) | Inhibitors of protein tyrosine kinase activity | |
CO6612202A2 (es) | Inhibidores heterparílicos bicíclicos de pde4 | |
NI200700318A (es) | Benzocicloheptapiridinas como inhibidores de la tirosina quinasa de receptor met | |
WO2010117423A3 (en) | Modulation of beta 2 adrenergic receptors by inhibitors of egln3 or pvhl |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |